


# Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer

National Institute for Clinical Excellence - Capecitabine Accord



Description: -

- Allenstown (N.H. : Town) -- Appropriations and expenditures -- Periodicals.

Breast -- Cancer -- Chemotherapy. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer

- Technology appraisal -- 62Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer

Notes: Cover title.

This edition was published in 2003



Filesize: 35.72 MB

Tags: #NICE #recommends #new #treatment #for #breast #and #bowel #cancer

## Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer

For patients with partial DPD deficiency, a lower starting dose may be considered.

## Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Evidence from three phase II single-arm studies is presented to supplement evidence from the EMBRACE trial. When there is no NICE technology appraisal guidance on a drug, treatment or other technology, decisions on funding should be made locally.

## Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Clinical Effectiveness One randomised controlled trial RCT and 3 non-RCTs were included in the review. Results: Treatment with sorafenib with capecitabine, compared with capecitabine with placebo, did not prolong median PFS 5.

### NICE recommends new treatment for breast and bowel cancer

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al

## Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

In terms of cost effectiveness, the ERG considers that the company substantially underestimated the size of the most probable base case deterministic ICER per QALY gained for eribulin versus capecitabine in the subgroup 1 population. Economic Evaluation Overview of Manufacturer's Cost-Effectiveness Review The MS provides a description of the review of published cost-effectiveness evidence undertaken by

the manufacturer.

**Eribulin for the treatment of locally advanced or metastatic breast cancer Clinical Practice Guidelines**

Therefore, the AC concluded that the 8 month cap on total treatment, as applied by the company, was not clinically plausible. Reducing the dose of capecitabine is common and the treatment can still be effective at a lower dose.

## Related Books

- [Pirates of Venus.](#)
- [Passione Secondo Thérèser](#)
- [General report of the agricultural state, and political circumstances, of Scotland](#)
- [House we live in - an environment reader](#)
- [Essays on the motherland - a brief history of modern Russia](#)